ALK and neoplasm: By contrast, response of children to ALK inhibitors such as crizotinib and ceritinib seems to be influenced by both histiotype and specific oncogenic aberration in paediatric patients with ALK gene aberrations.9 For this reason, many important targeted agents are not truly tumour agnostic.